Jazz Pharmaceuticals plc (JAZZ)
NASDAQ: JAZZ · Real-Time Price · USD
201.06
+5.75 (2.94%)
Apr 14, 2026, 4:00 PM EDT - Market closed
Jazz Pharmaceuticals Revenue
In the year 2025, Jazz Pharmaceuticals had annual revenue of $4.27B with 4.88% growth. Jazz Pharmaceuticals had revenue of $1.20B in the quarter ending December 31, 2025, with 10.09% growth.
Revenue (ttm)
$4.27B
Revenue Growth
+4.88%
P/S Ratio
2.90
Revenue / Employee
$1,476,673
Employees
2,890
Market Cap
12.38B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 4.27B | 198.64M | 4.88% |
| Dec 31, 2024 | 4.07B | 234.75M | 6.12% |
| Dec 31, 2023 | 3.83B | 174.83M | 4.78% |
| Dec 31, 2022 | 3.66B | 565.14M | 18.26% |
| Dec 31, 2021 | 3.09B | 730.67M | 30.91% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BioMarin Pharmaceutical | 3.22B |
| Exelixis | 2.32B |
| Arrowhead Pharmaceuticals | 1.09B |
| Madrigal Pharmaceuticals | 958.40M |
| Ionis Pharmaceuticals | 943.71M |
| Ascendis Pharma | 845.52M |
| Axsome Therapeutics | 638.50M |
| BridgeBio Pharma | 502.08M |
JAZZ News
- 5 days ago - Jazz Pharmaceuticals to Present Research on Epidiolex® (cannabidiol) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution at the 2026 American Academy of Neurology Annual Meeting - PRNewsWire
- 13 days ago - Jazz Pharmaceuticals to Participate in Needham Virtual Healthcare Conference - PRNewsWire
- 21 days ago - American Nutrition Association Announces Initiative with Jazz Pharmaceuticals to Advance Evidence-Based Sodium Reduction and Cardiovascular Health Education - PRNewsWire
- 27 days ago - Jazz Pharmaceuticals to Present Compelling Clinical and Pre-Clinical Data Advancing Oncology Research at AACR 2026 - PRNewsWire
- 4 weeks ago - Jazz Pharmaceuticals (JAZZ) Price Forecast: Multi-Year Base Signals Breakout Potential - FXEmpire
- 7 weeks ago - Jazz Pharmaceuticals Announces Full Year and Fourth Quarter 2025 Financial Results and Provides 2026 Financial Guidance - PRNewsWire
- 2 months ago - Jazz Pharmaceuticals to Participate in Upcoming Investor Conferences - PRNewsWire
- 2 months ago - Jazz Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Tuesday, February 24, 2026 - PRNewsWire